A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7304 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-31

Study Completion Date

2024-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin. This is a retrospective database analysis of health care claims data. All-cause costs as well as costs associated with recurrent VTE, major bleeding, and clinically relevant nonmajor bleeding will be assessed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients

NCT02048865

Venous Thromboembolism Cancer

COMPLETED PHASE2

A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the US

NCT04141228

Venous Thromboembolism (VTE)

COMPLETED

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study

NCT02559856

Venous Thromboembolism

COMPLETED PHASE4

Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism

NCT02585713

Cerebral Vein Thrombosis Deep Vein Thrombosis Gonadal Thrombosis +9 more

COMPLETED PHASE3

Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma

NCT06474182

Multiple Myeloma Total Knee Replacement

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

apixaban

patients treated with apixaban

No interventions assigned to this group

Low molecular weight heparin (LMWH)

patients treated with low molecular weight heparin

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021
* Evidence of active cancer
* At least 1 claim for apixaban or low molecular weight heparin (LMWH)
* Age 18 years or older

Exclusion Criteria

* diagnosis of atrial fibrillation/flutter
* procedure for mechanical heart valve or inferior vena cava filter
* VTE diagnosis in the baseline period
* anticoagulant therapy in the baseline period
* pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No